• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Lancet: Optimum timing of oseltamivir: lessons from Bangladesh

tetano

Editor, Senior Moderator
The Lancet Infectious Diseases, Volume 14, Issue 2, Pages 88 - 89, February 2014

doi:10.1016/S1473-3099(13)70287-1Cite or Link Using DOI
Published Online: 22 November 2013
Copyright ? 2014 Elsevier Ltd All rights reserved.
Optimum timing of oseltamivir: lessons from Bangladesh
Michael G Ison aEmail Address
Widespread resistance in currently circulating influenza A viruses has reduced the options for antiviral therapy against influenza. 1 , 2 Neuraminidase inhibitors, including laninamivir, oseltamivir, peramivir, and zanamivir, are the only approved anti-influenza drugs that have proven activity against circulating strains of influenza A and B viruses worldwide. 3 Oseltamivir is available in both pill and oral suspension formulations that can be given safely to patients of any age. 4?7 Furthermore, oselta ...



http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(13)70287-1/fulltext?rss=yes
 
Back
Top Bottom